This theoretical approach, combined with proteomic analysis in COVID-19 patients, might suggests new targets for specific treatments, as described for interaction between nsp10 and NKRF to mediate IL-8 expression, proposing this molecular mechanism as possible therapeutic target for anti-IL-8 and JUK inhibitor monoclonal antibodies50. This evidence concerns the gene CXCL8 and COVID-19.